|
1
|
Hashim D, Boffetta P, La Vecchia C, Rota
M, Bertuccio P, Malvezzi M and Negri E: The global decrease in
cancer mortality: Trends and disparities. Ann Oncol. 27:926–933.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bertuccio P, Turati F, Carioli G,
Rodriguez T, La Vecchia C, Malvezzi M and Negri E: Global trends
and predictions in hepatocellular carcinoma mortality. J Hepatol.
67:302–309. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sangiovanni A and Colombo M: Treatment of
hepatocellular carcinoma: Beyond international guidelines. Liver
Int. 36 Suppl 1:S124–S129. 2016. View Article : Google Scholar
|
|
4
|
Han K and Kim JH: Transarterial
chemoembolization in hepatocellular carcinoma treatment: Barcelona
clinic liver cancer staging system. World J Gastroenterol.
21:10327–10335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murata S, Mine T, Ueda T, Nakazawa K,
Onozawa S, Yasui D and Kumita S: Transcatheter arterial
chemoembolization based on hepatic hemodynamics for hepatocellular
carcinoma. ScientificWorldJournal. 2013:4798052013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peck-Radosavljevic M: Drug therapy for
advanced-stage liver cancer. Liver Cancer. 3:125–131. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Karakatsanis A, Papaconstantinou I,
Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of
microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c,
miR-221, miR-222, and miR-223 in patients with hepatocellular
carcinoma or intrahepatic cholangiocarcinoma and its prognostic
significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Girard M, Jacquemin E, Munnich A, Lyonnet
S and Henrion-Caude A: miR-122, a paradigm for the role of
microRNAs in the liver. J Hepatol. 48:648–656. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li C, Deng M, Hu J, Li X, Chen L, Ju Y,
Hao J and Meng S: Chronic inflammation contributes to the
development of hepatocellular carcinoma by decreasing miR-122
levels. Oncotarget. 7:17021–17034. 2016.PubMed/NCBI
|
|
10
|
Fornari F, Gramantieri L, Giovannini C,
Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM,
Tavolari S, et al: miR-122/cyclin G1 interaction modulates p53
activity and affects doxorubicin sensitivity of human
hepatocarcinoma cells. Cancer Res. 69:5761–5767. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsai WC, Hsu PW, Lai TC, Chau GY, Lin CW,
Chen CM, Lin CD, Liao YL, Wang JL, Chau YP, et al: MicroRNA-122, a
tumor suppressor microRNA that regulates intrahepatic metastasis of
hepatocellular carcinoma. Hepatology. 49:1571–1582. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal
K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer.
Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang X, Yuan T, Tschannen M, Sun Z, Jacob
H, Du M, Liang M, Dittmar RL, Liu Y, Liang M, et al:
Characterization of human plasma-derived exosomal RNAs by deep
sequencing. BMC Genomics. 14:3192013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Matsumura T, Sugimachi K, Iinuma H,
Takahashi Y, Kurashige J, Sawada G, Ueda M, Uchi R, Ueo H, Takano
Y, et al: Exosomal microRNA in serum is a novel biomarker of
recurrence in human colorectal cancer. Br J Cancer. 113:275–281.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Manier S, Liu CJ, Avet-Loiseau H, Park J,
Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, et
al: Prognostic role of circulating exosomal miRNAs in multiple
myeloma. Blood. 129:2429–2436. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fornari F, Ferracin M, Trerè D, Milazzo M,
Marinelli S, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borghi
A, et al: Circulating microRNAs, miR-939, miR-595, miR-519d and
miR-494, Identify Cirrhotic Patients with HCC. PLoS One.
10:e01414482015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sohn W, Kim J, Kang SH, Yang SR, Cho JY,
Cho HC, Shim SG and Paik YH: Serum exosomal microRNAs as novel
biomarkers for hepatocellular carcinoma. Exp Mol Med. 47:e1842015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang H, Hou L, Li A, Duan Y, Gao H and
Song X: Expression of serum exosomal microRNA-21 in human
hepatocellular carcinoma. Biomed Res Int.
2014:8648942014.PubMed/NCBI
|
|
20
|
Ding X, Ding J, Ning J, Yi F, Chen J, Zhao
D, Zheng J, Liang Z, Hu Z and Du Q: Circulating microRNA-122 as a
potential biomarker for liver injury. Mol Med Rep. 5:1428–1432.
2012.PubMed/NCBI
|
|
21
|
Laterza OF, Lim L, Garrett-Engele PW,
Vlasakova K, Muniappa N, Tanaka WK, Johnson JM, Sina JF, Fare TL,
Sistare FD, et al: Plasma MicroRNAs as sensitive and specific
biomarkers of tissue injury. Clin Chem. 55:1977–1983. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bala S, Petrasek J, Mundkur S, Catalano D,
Levin I, Ward J, Alao H, Kodys K and Szabo G: Circulating microRNAs
in exosomes indicate hepatocyte injury and inflammation in
alcoholic, drug-induced, and inflammatory liver diseases.
Hepatology. 56:1946–1957. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bihrer V, Friedrich-Rust M, Kronenberger
B, Forestier N, Haupenthal J, Shi Y, Peveling-Oberhag J, Radeke HH,
Sarrazin C, Herrmann E, et al: Serum miR-122 as a biomarker of
necroinflammation in patients with chronic hepatitis C virus
infection. Am J Gastroenterol. 106:1663–1669. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miyaaki H, Ichikawa T, Kamo Y, Taura N,
Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L
and Nakao K: Significance of serum and hepatic microRNA-122 levels
in patients with non-alcoholic fatty liver disease. Liver Int.
34:e302–e307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Morita K, Taketomi A, Shirabe K, Umeda K,
Kayashima H, Ninomiya M, Uchiyama H, Soejima Y and Maehara Y:
Clinical significance and potential of hepatic microRNA-122
expression in hepatitis C. Liver Int. 31:474–484. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nakao K, Miyaaki H and Ichikawa T:
Antitumor function of microRNA-122 against hepatocellular
carcinoma. J Gastroenterol. 49:589–593. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Halász T, Horváth G, Pár G, Werling K,
Kiss A, Schaff Z and Lendvai G: miR-122 negatively correlates with
liver fibrosis as detected by histology and FibroScan. World J
Gastroenterol. 21:7814–7823. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Conrad KD, Giering F, Erfurth C, Neumann
A, Fehr C, Meister G and Niepmann M: MicroRNA-122 dependent binding
of Ago2 protein to hepatitis C virus RNA is associated with
enhanced RNA stability and translation stimulation. PLoS One.
8:e562722013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sendi H: Dual role of miR-122 in molecular
pathogenesis of viral hepatitis. Hepat Mon. 12:312–314. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jangra RK, Yi M and Lemon SM: Regulation
of hepatitis C virus translation and infectious virus production by
the microRNA miR-122. J Virol. 84:6615–6625. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Csak T, Bala S, Lippai D, Satishchandran
A, Catalano D, Kodys K and Szabo G: microRNA-122 regulates
hypoxia-inducible factor-1 and vimentin in hepatocytes and
correlates with fibrosis in diet-induced steatohepatitis. Liver
Int. 35:532–541. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jin Y, Wang J, Han J, Luo D and Sun Z:
miR-122 inhibits epithelial-mesenchymal transition in
hepatocellular carcinoma by targeting Snail1 and Snail2 and
suppressing WNT/β-cadherin signaling pathway. Exp Cell Res.
360:210–217. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Burchard J, Zhang C, Liu AM, Poon RT, Lee
NP, Wong KF, Sham PC, Lam BY, Ferguson MD, Tokiwa G, et al:
microRNA-122 as a regulator of mitochondrial metabolic gene network
in hepatocellular carcinoma. Mol Syst Biol. 6:4022010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Köberle V, Kronenberger B, Pleli T, Trojan
J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem
S, Piiper A and Waidmann O: Serum microRNA-1 and microRNA-122 are
prognostic markers in patients with hepatocellular carcinoma. Eur J
Cancer. 49:3442–3449. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Waidmann O, Köberle V, Brunner F, Zeuzem
S, Piiper A and Kronenberger B: Serum microRNA-122 predicts
survival in patients with liver cirrhosis. PLoS One. 7:e456522012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Trebicka J, Anadol E, Elfimova N, Strack
I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J,
Sauerbruch T, et al: Hepatic and serum levels of miR-122 after
chronic HCV-induced fibrosis. J Hepatol. 58:234–239. 2013.
View Article : Google Scholar : PubMed/NCBI
|
